Comparing of Novus Therapeutics Inc. (NVUS) and aTyr Pharma Inc. (NASDAQ:LIFE)

Both Novus Therapeutics Inc. (NASDAQ:NVUS) and aTyr Pharma Inc. (NASDAQ:LIFE) are Biotechnology companies, competing one another. We will contrast their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Novus Therapeutics Inc. N/A 0.00 11.60M -1.37 0.00
aTyr Pharma Inc. N/A 0.00 39.67M -1.33 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Novus Therapeutics Inc. and aTyr Pharma Inc.

Profitability

Table 2 demonstrates the return on equity, return on assets and net margins of Novus Therapeutics Inc. and aTyr Pharma Inc.

Net Margins Return on Equity Return on Assets
Novus Therapeutics Inc. 0.00% -55.5% -51.7%
aTyr Pharma Inc. 0.00% -78.1% -53.6%

Risk and Volatility

A beta of 0.82 shows that Novus Therapeutics Inc. is 18.00% less volatile than Standard & Poor’s 500. Competitively, aTyr Pharma Inc.’s 187.00% volatility makes it more volatile than Standard & Poor’s 500, because of the 2.87 beta.

Liquidity

Novus Therapeutics Inc. has a Current Ratio of 10.7 and a Quick Ratio of 10.7. Competitively, aTyr Pharma Inc.’s Current Ratio is 5.4 and has 5.4 Quick Ratio. Novus Therapeutics Inc.’s better ability to pay short and long-term obligations than aTyr Pharma Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Novus Therapeutics Inc. and aTyr Pharma Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Novus Therapeutics Inc. 0 0 0 0.00
aTyr Pharma Inc. 0 2 0 2.00

Competitively aTyr Pharma Inc. has a consensus price target of $0.88, with potential upside of 80.70%.

Insider & Institutional Ownership

The shares of both Novus Therapeutics Inc. and aTyr Pharma Inc. are owned by institutional investors at 52.9% and 55.7% respectively. About 0.8% of Novus Therapeutics Inc.’s share are owned by insiders. Comparatively, aTyr Pharma Inc. has 0.4% of it’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Novus Therapeutics Inc. -20.46% -33.01% -39.07% -56.67% -36.7% -32.02%
aTyr Pharma Inc. -6.49% -9.83% -23.17% -41.75% -85.23% -83.54%

For the past year Novus Therapeutics Inc.’s stock price has smaller decline than aTyr Pharma Inc.

Summary

On 5 of the 7 factors Novus Therapeutics Inc. beats aTyr Pharma Inc.

Novus Therapeutics, Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of ear, nose, and throat products. Its lead product is a nasally-administered combination drug product (OP-02) intended to address the underlying cause of otitis media and Eustachian tube dysfunction (OM/ETD) conditions. The company also has a foam-based drug delivery technology platform (OP-01) that could be used to deliver drugs into the ear, nose, and sinus cavities. It is developing a foam-based combination drug-product to the external ear canal that is an improved treatment option for acute otitis externa. The company is headquartered in Irvine, California.

aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy (FSHD), early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. Its discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines. The company was founded in 2005 and is headquartered in San Diego, California.